Andrew Pierson, MD
Hematology & Oncology · Boise, IDNPI 1992760664
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,408 of the $3,821 with a category attached, or 89.2%. It is spread thinly across 42 manufacturers, the largest accounting for just 9.7% — the pattern of someone who eats at a lot of different presentations.
Across 163 payments — averaging $23.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$371
- Seagen Inc.$342
- E.r. Squibb & Sons, L.L.C.$318
- AstraZeneca$318
- Genentech USA, Inc.$226
- Novartis$225
- plus $2K from 36 others
Across 12 payments — averaging $1590.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$16K
- AstraZeneca$3K
What the payments were for
- Food & beverage$3,40889%
- Education$41411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 12 | $371 |
| Seagen Inc. | 10 | $342 |
| E.r. Squibb & Sons, L.L.C. | 14 | $318 |
| AstraZeneca | 8 | $318 |
| Genentech USA, Inc. | 12 | $226 |
| Novartis | 11 | $225 |
| Incyte Corporation | 5 | $194 |
| Merck | 7 | $159 |
| Bristol Myers Squibb | 7 | $157 |
| Pfizer | 8 | $127 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $110 |
| Sanofi | 6 | $107 |
| EMD Serono, Inc. | 5 | $92 |
| Agios Pharmaceuticals, Inc. | 1 | $75 |
| Genentech, Inc. | 2 | $70 |
| Pharmaessentia USA Corporation | 3 | $67 |
| Astellas Pharma US Inc | 3 | $62 |
| GSK | 3 | $62 |
| Mirati Therapeutics, Inc. | 3 | $60 |
| Rigel Pharmaceuticals, Inc. | 2 | $58 |
| AbbVie | 3 | $53 |
| Array Biopharma Inc | 2 | $48 |
| Bayer | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Eisai Inc. | 3 | $46 |
| Lilly USA, LLC | 3 | $44 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| Amgen | 2 | $32 |
| ADC Therapeutics America, Inc. | 2 | $32 |
| Acrotech Biopharma Inc. | 1 | $20 |
| Blueprint Medicines Corporation | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| Puma Biotechnology, Inc. | 1 | $17 |
| Exelixis Inc. | 1 | $15 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Sirtex Medical Inc | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| Gilead | 1 | $13 |
| Clovis Oncology, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,821 in reported general payments places this provider in the 60th percentile of 34 hematology & oncology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 32 | $477,605 |
| RevlimidLenalidomide | 19 | $330,485 |
| JakafiRuxolitinib Phosphate | 18 | $309,556 |
| NubeqaDarolutamide | 22 | $294,242 |
| PomalystPomalidomide | 13 | $226,844 |
| VerzenioAbemaciclib | 14 | $214,968 |
| ErleadaApalutamide | 14 | $205,850 |
| CalquenceAcalabrutinib Maleate | 12 | $176,600 |
| LonsurfTrifluridine/Tipiracil Hcl | 12 | $106,743 |
| VenclextaVenetoclax | 14 | $84,926 |
| EliquisApixaban | 72 | $49,995 |
| GranixTbo-Filgrastim | 12 | $25,437 |
| CreonLipase/Protease/Amylase | 11 | $9,927 |
| Enoxaparin Sodium | 12 | $7,551 |
| Prochlorperazine Maleate | 115 | $2,469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $127 | $527,599104 claims |
| Bristol Myers SquibbRevlimid | $157 | $330,48519 claims |
| Incyte CorporationJakafi | $194 | $309,55618 claims |
| BayerNubeqa | $48 | $294,24222 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $318 | $226,84413 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $44 | $215,23557 claims |
| Johnson & JohnsonErleada | $371 | $205,85014 claims |
| AstraZenecaCalquence | $318 | $176,60012 claims |
| AbbVieVenclexta, Creon | $53 | $94,85325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 34 hematology & oncology providers in Idaho.
Other hematology & oncology in Boise
- Olga DermanBoise$3K
- Dan ZuckermanBoise$3K
- William KreisleBoise$1K
- Kerry PulverBoise$802
- Shane AhlersBoise$555
- Nicholas GordenBoise$519
- Zachary BensonBoise$477
- Anuhya KommalapatiBoise$405
- Paul MontgomeryBoise$75
- Andrew DysartBoise$20
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.